{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:10:32Z","timestamp":1790539832034,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.therap.2020.05.008","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T11:41:34Z","timestamp":1589888494000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bupr\u00e9norphine d\u2019action prolong\u00e9e\u00a0: quelles perspectives pour la pratique clinique\u00a0?"],"prefix":"10.1016","author":[{"given":"Mathieu","family":"Chappuy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Trojak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Nubukpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Bachellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bendimerad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Brousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.therap.2020.05.008_bib0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.therap.2020.05.008_bib0220","series-title":"French Monitoring Centre for Drugs and Drug Addiction, Drugs, key figures","year":"2019"},{"key":"10.1016\/j.therap.2020.05.008_bib0225","series-title":"French monitoring centre for drugs and drug addiction, evolution of the number of overdose deaths since 1985","year":"2019"},{"issue":"18","key":"10.1016\/j.therap.2020.05.008_bib0230","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","article-title":"Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus","volume":"18","author":"Dematteis","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.therap.2020.05.008_bib0235","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.revmed.2016.12.024","article-title":"Misuse and dependence on prescription opioids: prevention, identification and treatment","volume":"38","author":"Rolland","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2020.05.008_bib0240","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2020.05.008_bib0245","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride","volume":"193","author":"Dole","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.05.008_bib0250","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1001\/jama.2008.648","article-title":"Methadone maintenance 4\u00a0decades later: thousands of lives saved but still controversial","volume":"300","author":"Kleber","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.05.008_bib0255","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2020.05.008_bib0260","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.therap.2020.05.008_bib0265","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"J Addict Med"},{"issue":"1","key":"10.1016\/j.therap.2020.05.008_bib0270","first-page":"S17","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"Am J Addict"},{"issue":"5","key":"10.1016\/j.therap.2020.05.008_bib0275","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","article-title":"Why buprenorphine is so successful in treating opiate addiction in France","volume":"9","author":"Fatseas","year":"2007","journal-title":"Curr Psychiatry Rep"},{"issue":"7","key":"10.1016\/j.therap.2020.05.008_bib0280","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"10.1016\/j.therap.2020.05.008_bib0285","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1080\/14656566.2016.1209486","article-title":"Buprenorphine dosing choices in specific populations: review of expert opinion","volume":"17","author":"Maremmani","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.therap.2020.05.008_bib0290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40267-017-0408-8","article-title":"Buprenorphine oral lyophilisate (Espranor\u00ae) in the substitution treatment of opioid dependence: a profile of its use","volume":"33","author":"Lyseng-Williamson","year":"2017","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.therap.2020.05.008_bib0295","series-title":"French monitoring centre for drugs and drug addiction, opioid agonist treatment dashboard 2019 update","year":"2019"},{"key":"10.1016\/j.therap.2020.05.008_bib0300","series-title":"European Medicine Agency. Sixmo\u00ae: summary of product characteristics","year":"2020"},{"issue":"12","key":"10.1016\/j.therap.2020.05.008_bib0305","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"issue":"14","key":"10.1016\/j.therap.2020.05.008_bib0310","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.therap.2020.05.008_bib0315","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial","volume":"316","author":"Rosenthal","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.05.008_bib0320","series-title":"Food and Drug Administration. Sublocade\u00ae: summary of product characteristics","year":"2020"},{"issue":"10173","key":"10.1016\/j.therap.2020.05.008_bib0325","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.therap.2020.05.008_bib0330","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JCP.0000000000000434","article-title":"Sublocade then published in sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder","volume":"36","author":"Nasser","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2020.05.008_bib0335","series-title":"Financial results","author":"Indivior","year":"2019"},{"key":"10.1016\/j.therap.2020.05.008_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.11.004","article-title":"Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study","volume":"110","author":"Ling","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.therap.2020.05.008_bib0345","series-title":"Buvidal\u00ae: summary of product characteristics","author":"European Medecines Agency","year":"2019"},{"key":"10.1016\/j.therap.2020.05.008_bib0350","series-title":"Transparency committee \u2013 Notice of 25\/07\/2018\u00a0Orobupr\u00e9\u00ae","author":"High Authority of Health","year":"2018"},{"issue":"6","key":"10.1016\/j.therap.2020.05.008_bib0355","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.therap.2020.05.008_bib0360","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder","volume":"114","author":"Frost","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2020.05.008_bib0365","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2020.05.008_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: qualitative study of people whouse or have used heroin","volume":"189","author":"Neale","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.therap.2020.05.008_bib0375","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17425247.2019.1649252","article-title":"What place for prolonged-release buprenorphine depot-formulation Buvidal\u00ae in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine","volume":"16","author":"Vorspan","year":"2019","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.therap.2020.05.008_bib0380","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12954-019-0296-4","article-title":"Prolonged-release opioid agonist therapy: qualitative study exploring patients\u2019 views of 1-week, 1-month, and 6-month buprenorphine formulations","volume":"16","author":"Neale","year":"2019","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.therap.2020.05.008_bib0385","article-title":"Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia","author":"Larance","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2020.05.008_bib0390","series-title":"A-t-on besoin de traitements de substitution \u00ab\u00a0long acting\u00a0\u00bb en France\u00a0?","author":"Bachellier","year":"2019"},{"key":"10.1016\/j.therap.2020.05.008_bib0395","series-title":"Bupr\u00e9norphine injectable","author":"Psychoactif Forum [French]","year":"2017"},{"key":"10.1016\/j.therap.2020.05.008_bib0400","series-title":"Subutex\u00a0: une injection par mois par l\u2019infirmi\u00e8re","author":"Psychoactif Forum [French]","year":"2018"},{"key":"10.1016\/j.therap.2020.05.008_bib0405","series-title":"Bupr\u00e9norphine en implant sous-cutan\u00e9","author":"Psychoactif Forum [French]","year":"2016"},{"key":"10.1016\/j.therap.2020.05.008_bib0410","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/SAR.S155843","article-title":"Depot buprenorphine injection in the management of opioid use disorder: from development to implementation","volume":"10","author":"Ling","year":"2019","journal-title":"Subst Abuse Rehabil"},{"key":"10.1016\/j.therap.2020.05.008_bib0415","series-title":"Opioid dependence: buprenorphine prolonged-release injection (Buvidal). Evidence summary [ES19]","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"10.1016\/j.therap.2020.05.008_bib0210","series-title":"CEIP","author":"ANSM","year":"2019"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:37:47Z","timestamp":1775684267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720300986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":42,"alternative-id":["S0040595720300986"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bupr\u00e9norphine d\u2019action prolong\u00e9e\u00a0: quelles perspectives pour la pratique clinique\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}